145349-17-3

Basic information

• Product Name: 2-Fluoro-2-Methylpropyl trifluoroMethanesulfonate
• Synonyms: 2-Fluoro-2-Methylpropyl trifluoroMethanesulfonate;OJFXAMILNHYNSV-UHFFFAOYSA-N
• CAS NO: 145349-17-3
• Molecular Formula: C₅H₈F₄O₃S
• Molecular Weight: 224.1738328
• Mol File: 145349-17-3.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 80 °C(Press: 55-60 Torr)
• Appearance: /
• Density: 1.397±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2-Fluoro-2-Methylpropyl trifluoroMethanesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Fluoro-2-Methylpropyl trifluoroMethanesulfonate(145349-17-3)
• EPA Substance Registry System: 2-Fluoro-2-Methylpropyl trifluoroMethanesulfonate(145349-17-3)

Safety Data

• Hazardous Substances Data: 145349-17-3(Hazardous Substances Data)

Usage

Uses

2-Fluoro-2-methylpropyl Trifluoromethanesulfonate is a useful compound for optimization of binding motif to AZD9496 in medicinal chemistry.

Upstream product

• 358-23-6 trifluoromethylsulfonic anhydride 
• 3109-99-7 2-fluoro-2-methyl-propan-1-ol 
• 1493-13-6 trifluorormethanesulfonic acid 
• 1025373-45-8 trifluoromethanesulfonic acid anhydride 

Downstream Products

• 883443-08-1 (2S,5R)-5-[(1S,2S)-1-benzyloxy-2-dibenzylamino-3-(3,5-difluorophenylpropyl)-2-(2-fluoro-2-methylpropoxy)]-morpholine-4-carboxylic acid tert-butyl ester 
• 19869-79-5 1-Iod-2-fluor-2-methyl-propan 
• 19869-78-4 1-bromo-2-fluoro-2-methylpropane 

Relevant articles and documents

Tricyclic Indazoles - A Novel Class of Selective Estrogen Receptor Degrader Antagonists

Herein, we report the identification and synthesis of a series of tricyclic indazoles as a novel class of selective estrogen receptor degrader antagonists. Replacement of a phenol, present in our previously reported tetrahydroisoquinoline scaffold, with an indazole group led to the removal of a reactive metabolite signal in an in vitro glutathione trapping assay. Further optimization, guided by X-ray crystal structures and NMR conformational work, varied the alkyl side chain and pendant aryl group and resulted in compounds with low turnover in human hepatocytes and enhanced chemical stability. Compound 9 was profiled as a representative of the series in terms of pharmacology and demonstrated the desired estrogen receptor α degrader-antagonist profile and demonstrated activity in a xenograft model of breast cancer.

REGIMENS OF ESTROGEN RECEPTOR ANTAGONISTS

Provided herein are methods of administering estrogen receptor antagonists for use in treatment of cancer. The antagonists (such as a hexahydro pyrido[3,4-b]indole, AZD9496, RAD-1901, ARN-810, endoxifen, or fulvestrant) may be an inhibitor of both activating function 1 and activating function 2 of the estrogen receptor. Also provided are combinations of above inhibitors with a secondary agent, which is a CDK 4/6 inhibitor (such as, palbocociclib, ribociclib, abemaciclib, lerociclib, and trilaciclib).

INHIBITING HUMAN INTEGRIN α4β7

Disclosed are small molecule antagonists of human α4β7 integrin, and methods of using them to treat a number of diseases and conditions.